Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF^V600E-Mutant Human Glioma

Keyphrases

• Human Glioma 100%
• Acquired Resistance 100%
• BRAF Inhibitor (BRAFi) 100%
• BRAF V600E mutant 100%
• Glioma 80%
• Resistance Mechanism 80%
• Knockdown 60%
• Targeted Therapy 40%
• Expression Pattern 40%
• Functional Validation 40%
• Possible Mechanisms 20%
• Genetic Modification 20%
• BRCA1-associated Protein 1 (BAP1) 20%
• Glioma Cell Lines 20%
• DNA Sequencing 20%
• RNA Sequencing (RNA-seq) 20%
• N-15 20%
• Tissue Sampling 20%
• Ill-defined 20%
• Combination Therapy 20%
• MEK Inhibitor (MEKi) 20%
• Paired Samples 20%
• BRAF V600E 20%
• EGFR Expression 20%
• ERK Pathway 20%
• Personalized Approach 20%
• RNA-seq Analysis 20%
• Treatment Emergent 20%
• Glioma Subtypes 20%
• MAP2K1 20%
• ERRFI1 20%
• Adaptive Resistance 20%
• EGFR Phosphorylation 20%
• ANKHD1 20%
• Overcoming Resistance 20%
• Patient-derived 20%
• Epidermal Growth Factor Receptor Inhibitors (EGFRI) 20%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• RNA Sequence 100%
• Targeted Therapy 100%
• Upregulation 50%
• BAP1 50%
• Wild Type 50%
• MAP2K1 50%
• Genomics 50%
• phosphorylation 50%

Medicine and Dentistry

• Ganglioglioma 100%
• Targeted Therapy 33%
• RNA Sequence 33%
• In Vitro 16%
• Epidermal Growth Factor Receptor 16%
• Glioma Cell Line 16%
• Upregulation 16%
• Combination Therapy 16%
• EGFR Inhibitors 16%
• Genetics 16%
• phosphorylation 16%